rosiglitazone has been researched along with Alveolar Bone Atrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, JB; Alves, PM; Campos-Júnior, JC; Cunha, FQ; Gonçalves, RB; Hassumi, MY; Kawai, T; Napimoga, MH; Silva-Filho, VJ; Vieira, SM | 1 |
| Britti, D; Cuzzocrea, S; De Majo, M; Di Paola, R; Genovese, T; Maiere, D; Mazzon, E; Zito, D | 1 |
2 other study(ies) available for rosiglitazone and Alveolar Bone Atrophy
| Article | Year |
|---|---|
PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis.
Topics: Acid Phosphatase; Administration, Oral; Alveolar Bone Loss; Animals; Cell Differentiation; Cell Line; Hypoglycemic Agents; Immunohistochemistry; Isoenzymes; Male; Osteoclasts; Osteogenesis; Periodontitis; PPAR gamma; RANK Ligand; Rats; Rats, Wistar; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazolidinediones | 2009 |
Rosiglitazone reduces the evolution of experimental periodontitis in the rat.
Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ligation; Male; Neutrophil Infiltration; Nitric Oxide Synthase Type II; Periodontitis; Poly(ADP-ribose) Polymerase Inhibitors; PPAR gamma; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Tyrosine | 2006 |